atai Life Sciences (ATAI)
(Delayed Data from NSDQ)
$1.22 USD
-0.04 (-3.17%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.22 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
atai Life Sciences N.V. [ATAI]
Reports for Purchase
Showing records 1 - 20 ( 67 total )
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Key Takeaways From Biotech Breakthroughs Event: A Long Position in Short-Acting Psychedelics
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Neuro Perspectives Conference Takeaways: Investable Opportunities in Mental Health and Neurological Disorders
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Lykos Lessons: Functional Unblinding, Treatment Durability, Role of Psychotherapy, Safety, and a Proposed REMS
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
1Q24 Results; BPL-003 Phase 2b Depression Data on Track for 2H24; Early-Stage Pipeline Progressing Well; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Key Takeaway From Biotech Breakthroughs Oncology Event: The Rise of PRAME-Targeted Therapies
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
BPL-003 Phase 2 Depression Data Expected 2H24; Multiple Programs Progressing in Phase 1; Modulating PT to $15; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
BPL-003 Generates Encouraging Phase 2a TRD Data, Providing Positive Read-Through to Phase 2b Outcome in 2H24; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Emerging Neuro Leader Poised to Shine; Multiple Phase 2 Readouts Expected in 2024 and 2025; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Transformational Beckley Collaboration to Drive Leadership in Psychedelics in Psychiatry; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
EMP-01 Generates Promising Phase 1 Data in Next Generation Psychedelic Program Addressing PTSD; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
3Q23 Results; Early Stage Data Emerging; RL-007 Phase 2a Data Expected 2H24; Unveils New Psychedelics; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Novel Formulation of DMT Clears Another Hurdle; Plans Phase 1b in 1H24 Before Moving to Phase 2; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Key Takeaways From 25th Annual Global Conference: Multiple Underappreciated Programs to Shine in 2H23 and 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
2Q23 Results; Early Stage Psychedelic Compounds Advancing; RL-007 in CIAS on Track for Phase 2 Data in 2H24; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Lead Compounds VLS-01 in Depression and GRX-917 in Anxiety on Track; Multiple Catalysts Expected in 2H23; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
1Q23 Results; Multiple Psychedelic Data Readouts Expected in 2023; Non-Psychedelic Programs Advancing on Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
4Q22 Results; Multiple Psychoactive Agents to Generate Early Stage Data in 2023; Non-Psychedelic Pipeline Progressing
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Bullish Start to the Year for Psychedelic Drug Development Companies Ahead of a Plethora of Potential Positive Events
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Remains Focused on Advancing Broad Pipeline Following Recent Setbacks; Lowering Price Target to $20; Maintain Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P